Also
Weekly Focus | Business : 3billion and DeepLife Join Forces to Revolutionize Drug Discovery with AI
South Korean biotech company 3billion and French AI drug discovery specialist DeepLife have signed a joint research agreement at Bio-Europe 2026, marking a new step in French-Korean cooperation in biotechnology and artificial intelligence.
Combining AI and Genomics to Advance Drug Discovery
Announced on November 10, 2026, the partnership aims to accelerate the identification of new therapeutic targets and the development of innovative drug candidates by combining the companies' complementary expertise.
3billion brings its genomic analysis capabilities, based on data from more than 120,000 patients, alongside its proprietary AI-powered drug design technology. DeepLife contributes its TwinCell virtual cell platform, which leverages over 100 million single-cell data points to analyze disease mechanisms and validate potential therapeutic targets.
By integrating human genetic evidence with AI-driven cellular analysis, the companies seek to reduce risks in early-stage drug development, improve the selection of promising drug candidates, and accelerate pharmaceutical innovation.
Strengthening French-Korean Cooperation in Biotechnology
Beyond research, 3billion and DeepLife aim to pursue joint development and global licensing opportunities with international pharmaceutical companies across multiple therapeutic areas.
The partnership highlights the growing potential of French-Korean collaboration in AI, biotechnology, and healthcare, bringing together complementary technologies to advance next-generation drug discovery.
Source:Seoul Economic Daily, November 10, 2026.
Follow the FKCCI on social media to stay informed about upcoming events, insights and highlights throughout 2026.
LinkedIn I Instagram I Facebook I Twitter I YouTube I Naver Blog
